A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
Completed · Phase 2 · Has a placebo group
Conditions studied: Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease
In brief
The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)
Key facts
- Study ID
- NCT03847909
- Run by
- Novo Nordisk A/S
- People needed
- 35
- Starts
- 2019-10-28
- Expected to finish
- 2021-06-29
- Last updated by the study team
- 2024-05-22
Who can join
Age: 6 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Trial Site — San Francisco, California, United States
- Clinical Trial Site — Boston, Massachusetts, United States
- Clinical Trial Site — Rochester, Minnesota, United States
- Clinical Trial Site — New York, New York, United States
- Clinical Trial Site — Pittsburgh, Pennsylvania, United States
- Clinical Trial Site — Herston, Australia
- Clinical Trial Site — Parkville, Australia
- Clinical Trial Site — Hamilton, Canada
- Clinical Trial Site — Bron, France
- Clinical Trial Site — Paris, France
- Clinical Trial Site — Bonn, Germany
- Clinical Trial Site — Heidelberg, Germany
- Clinical Trial Site — Jerusalem, Israel
- Clinical Trial Site — Roma, Italy
- Clinical Trial Site — Nagoya, Japan
- Clinical Trial Site — Tochigi, Japan
- Clinical Trial Site — Tokyo, Japan
- Clinical Trial Site — Beirut, Lebanon
- Clinical Trial Site — Beirut, Lebanon
- Clinical Trial Site — Amsterdam, Netherlands
- Clinical Trial Site — Auckland, New Zealand
- Clinical Trial Site — Bialystok, Poland
- Clinical Trial Site — Bucharest, Romania
- Clinical Trial Site — Barcelona, Spain
- Clinical Trial Site — Santa Cruz, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.